Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam Radiation

No AccessJournal of UrologyClinical Urology: Original Article1 Aug 1995Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam Radiation Gerald E.* Hanks, W. Robert Lee, and Timothy E. Schultheiss Gerald E.* HanksGerald E.* Hanks , W. Robert LeeW. Robert Lee , and Timothy E. SchultheissTimothy E. Schultheiss View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67073-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We demonstrate the 5-year survival rate for patients with prostate cancer treated by irradiation, the value of the conformal technique and prostate specific antigen (PSA) doubling times after irradiation. Materials and Methods: The outcome of 502 consecutive patients with stages T1 to T3 prostate cancer treated by irradiation alone is reported. PSA doubling times before and after failure are reported for 13 patients and posttreatment PSA doubling times are reported for 93 consecutive patients in whom radiation failed. Results: The actuarial survival with biochemical freedom from disease (PSA nadir 1.5 or less not increasing) at 5 years was 44 percent for all patients, 50 percent for the conformal treatment group and 39 percent for the conventional therapy group. PSA doubling times after radiation failure were variable, with 42 percent greater than 12 months. Conclusions: The 5-year survival rate for patients with prostate cancer treated by irradiation is excellent. The conformal technique is superior to conventional therapy and there is no evidence that irradiation accelerates the growth rate of prostate cancer. References 1 : Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol.1991; 145: 907. Link, Google Scholar 2 : The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A.1993; 269: 57. Google Scholar 3 : Localized prostate cancer treated by external beam radiotherapy alone: serum PSA driven outcome analysis. J. Clin. Oncol.1995; 13: 464. Google Scholar 4 : Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol.1994; 151: 640. Link, Google Scholar 5 : Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol.1993; 11: 2158. Google Scholar 6 : Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer.1993; 20: 713. Crossref, Medline, Google Scholar 7 : The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80 percent of patients. J. Urol.1993; 150: 1856. Abstract, Google Scholar 8 : Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol.1991; 146: 1046. Link, Google Scholar 9 : Prostate specific antigen and external beam radiation therapy in prostate cancer. Cancer1991; 67: 412. Google Scholar 10 : PSA confirmation of cure at 10 years of the T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int. J. Rad. Oncol. Biol. Phys.1994; 30: 289. Google Scholar 11 : Radical radiation therapy in the management of loco-regionally confined prostate cancer: analysis of results using PSA as a tumor marker. Int. Cong. Rad. Oncol.1993; . abstract 348. Google Scholar 12 Corn, B. W. and Hanks, G. E.: Superior PSA response achieved with conformal radiation therapy of prostate cancer. Int. J. Rad. Oncol. Biol. Phys., in press. Google Scholar 13 : Optimizing the radiation treatment and outcome of prostate cancer. Int. J. Rad. Oncol. Biol. Phys.1985; 11: 1235. Google Scholar 14 : Carcinoma of the prostate stage B and C: lack of influence of duration of radiotherapy on tumor control and treatment morbidity. Int. J. Rad. Oncol. Biol. Phys.1990; 19: 561. Google Scholar 15 : Patterns of care and RTOG studies in prostate cancer: long term survival, hazard rate observations, and possibilities of cure. Int. J. Rad. Oncol. Biol. Phys.1994; 28: 39. Google Scholar 16 : Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results. Urology1994; 43: 640. Google Scholar Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byD’AMICO A, WHITTINGTON R, MALKOWICZ S, WEINSTEIN M, TOMASZEWSKI J, SCHULTZ D, RHUDE M, ROCHA S, WEIN A and RICHIE J (2018) PREDICTING PROSTATE SPECIFIC ANTIGEN OUTCOME PREOPERATIVELY IN THE PROSTATE SPECIFIC ANTIGEN ERAJournal of Urology, VOL. 166, NO. 6, (2185-2188), Online publication date: 1-Dec-2001.CRITZ F, WILLIAMS W, LEVINSON A, BENTON J, HOLLADAY C and SCHNELL F (2018) SIMULTANEOUS IRRADIATION FOR PROSTATE CANCER: INTERMEDIATE RESULTS WITH MODERN TECHNIQUESJournal of Urology, VOL. 164, NO. 3 Part 1, (738-743), Online publication date: 1-Sep-2000.D’AMICO A, SCHULTZ D, SCHNEIDER L, HURWITZ M, KANTOFF P and RICHIE J (2018) COMPARING PROSTATE SPECIFIC ANTIGEN OUTCOMES AFTER DIFFERENT TYPES OF RADIOTHERAPY MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE CANCER HIGHLIGHTS THE IMPORTANCE OF CONTROLLING FOR ESTABLISHED PROGNOSTIC FACTORSJournal of Urology, VOL. 163, NO. 6, (1797-1801), Online publication date: 1-Jun-2000.EASTHAM J and KATTAN M (2018) DISEASE RECURRENCE IN BLACK AND WHITE MEN UNDERGOING RADICAL PROSTATECTOMY FOR CLINICAL STAGE T1-T2 PROSTATE CANCERJournal of Urology, VOL. 163, NO. 1, (143-145), Online publication date: 1-Jan-2000.STONE N and STOCK R (2018) PROSTATE BRACHYTHERAPY: TREATMENT STRATEGIESJournal of Urology, VOL. 162, NO. 2, (421-426), Online publication date: 1-Aug-1999. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 160, NO. 1, (94-95), Online publication date: 1-Jul-1998.GRANFORS T, MODIG H, DAMBER J and TOMIC R (2018) COMBINED ORCHIECTOMY AND EXTERNAL RADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR NONMETASTATIC PROSTATE CANCER WITH OR WITHOUT PELVIC LYMPH NODE INVOLVEMENT: A PROSPECTIVE RANDOMIZED STUDYJournal of Urology, VOL. 159, NO. 6, (2030-2034), Online publication date: 1-Jun-1998.GROSSFELD G, OLUMI A, CONNOLLY J, CHEW K, GIBNEY J, BHARGAVA V, WALDMAN F and CARROLL P (2018) LOCALLY RECURRENT PROSTATE TUMORS FOLLOWING EITHER RADIATION THERAPY OR RADICAL PROSTATECTOMY HAVE CHANGES IN KI-67 LABELING INDEX, P53 AND BCL-2 IMMUNOREACTIVITYJournal of Urology, VOL. 159, NO. 5, (1437-1443), Online publication date: 1-May-1998.GARZOTTO M and WAJSMAN Z (2018) ANDROGEN DEPRIVATION WITH SALVAGE SURGERY FOR RADIORECURRENT PROSTATE CANCER: RESULTS AT 5-YEAR FOLLOWUPJournal of Urology, VOL. 159, NO. 3, (950-955), Online publication date: 1-Mar-1998.Vicini F, Horwitz E, Gonzalez J and Martinez A (2018) Treatment Options for Localized Prostate Cancer Based on Pretreatment Serum Prostate Specific Antigen LevelsJournal of Urology, VOL. 158, NO. 2, (319-325), Online publication date: 1-Aug-1997. Volume 154Issue 2August 1995Page: 456-459 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Gerald E.* Hanks More articles by this author W. Robert Lee More articles by this author Timothy E. Schultheiss More articles by this author Expand All Advertisement PDF downloadLoading ...